

according to the Hazardous Products Regulations

Interferon Alfa-2b Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
5.8	09/30/2023	42803-00018	Date of first issue: 01/07/2015

SECTION 1. IDENTIFICATION

Product name	:	Interferon Alfa-2b Liquid Formulation
Other means of identification	:	No data available

Manufacturer or supplier's details

Company name of supplier	:	Merck & Co., Inc
Address	:	126 E. Lincoln Avenue
		Rahway, New Jersey U.S.A. 07065
Telephone	:	908-740-4000
Emergency telephone	:	1-908-423-6000
E-mail address	:	EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use	: Pharmaceutical
Restrictions on use	: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations					
Reproductive toxicity	:	Category 1B			
Specific target organ toxicity - repeated exposure	:	Category 2 (Blood, Bone marrow)			
GHS label elements					
Hazard pictograms	:				
Signal Word	:	Danger			
Hazard Statements	:	H360FD May damage fertility. May damage the unborn child. H373 May cause damage to organs (Blood, Bone marrow) through prolonged or repeated exposure.			
Precautionary Statements	:	Prevention:			
		 P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapors. P280 Wear protective gloves, protective clothing, eye protection and face protection. 			
		Response: P308 + P313 IF exposed or concerned: Get medical attention.			
		Storage: P405 Store locked up.			

according to the Hazardous Products Regulations



Interferon Alfa-2b Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
5.8	09/30/2023	42803-00018	Date of first issue: 01/07/2015

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
m-Cresol	Phenol, 3- methyl-	108-39-4	>= 0.1 - < 1 *
Interferon alfa-2b	No data availa- ble	98530-12-2	>= 0.001 - < 0.1 *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed Protection of first-aiders	:	May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. First Aid responders should pay attention to self-protection,
Notes to physician	:	and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media :

Water spray Alcohol-resistant foam



Version 5.8	Revision Date: 09/30/2023		0S Number: 803-00018	Date of last issue: 04/04/2023 Date of first issue: 01/07/2015	
media Specil fightin Hazar ucts	fic hazards during fire	::	Carbon dioxide (CO2) Dry chemical None known. Exposure to combustion products may be a hazard to heal No hazardous combustion products are known Use extinguishing measures that are appropriate to local c cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to		
	al protective equipment e-fighters	:	Remove undamaged containers from fire area if it is safe to so. Evacuate area. In the event of fire, wear self-contained breathing apparatus Use personal protective equipment.		
SECTION	6. ACCIDENTAL RELE	AS	E MEASURES		
tive eo	nal precautions, protec- quipment and emer- procedures	:		ective equipment. ing advice (see section 7) and personal ent recommendations (see section 8).	
Enviro	onmental precautions	:	Prevent spreading oil barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g., by containment or se of contaminated wash water. should be advised if significant spillages	
	ods and materials for inment and cleaning up	:	For large spills, pr containment to ke can be pumped, s container. Clean up remainir absorbent. Local or national r disposal of this ma employed in the c determine which r Sections 13 and 1	absorbent material. ovide diking or other appropriate ep material from spreading. If diked material tore recovered material in appropriate ng materials from spill with suitable egulations may apply to releases and aterial, as well as those materials and items leanup of releases. You will need to egulations are applicable. 5 of this SDS provide information regarding tional requirements.	

SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE
Local/Total ventilation		CONTROLS/PERSONAL PROTECTION section. If sufficient ventilation is unavailable, use with local exhaust
	•	ventilation.
Advice on safe handling	:	Do not get on skin or clothing.



Version 5.8	Revision Date: 09/30/2023	SDS Number: 42803-00018	Date of last issue: 04/04/2023 Date of first issue: 01/07/2015			
		Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safet practice, based on the results of the workplace exposure assessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to th environment.				
Conditions for safe storage		: Keep in properly labeled containers. Store locked up. Keep tightly closed.				
Materials to avoid		 Store in accordance with the particular national regulation Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases 				

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ingredients with workplace control parameters							
Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis			
m-Cresol	108-39-4	TWA	5 ppm 22 mg/m³	CA AB OEL			
		TWAEV (in- halable frac- tion and va- pour)	20 mg/m ³	CA QC OEL			
		TWA	10 mg/m ³	CA BC OEL			
		TWA (Inhalable fraction and vapor)	20 mg/m ³	ACGIH			
Interferon alfa-2b	98530-12-2	TWA	0.2 µg/m3 (OEB 5)	Internal			
		Wipe limit	2 µg/100 cm ²	Internal			

Ingredients with workplace control parameters

Engineering measures

: Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment



according to the Hazardous Products Regulations

Interferon Alfa-2b Liquid Formulation

Version 5.8	Revision Date: 09/30/2023	SDS Number: 42803-00018		Date of last issue: 04/04/2023 Date of first issue: 01/07/2015		
			nnology desigr workplace.	ned to prevent leakage of compounds into		
Perso	onal protective equipr	nent				
Resp	Respiratory protection		No personal respiratory protective equipment normally required.			
Hand	protection					
M	aterial	: Che	emical-resistar	nt gloves		
	emarks protection	: We If th mis We pote	e work enviror ts or aerosols, ar a faceshield	gloving. ses with side shields or goggles. nment or activity involves dusty conditions, wear the appropriate goggles. d or other full face protection if there is a t contact to the face with dusts, mists, or		
Skin	Skin and body protection		rk uniform or la ditional body g deing perforr bosable suits)	aboratory coat. arments should be used based upon the ned (e.g., sleevelets, apron, gauntlets, to avoid exposed skin surfaces. degowning techniques to remove potentially thing.		
Hygie	Hygiene measures		xposure to che flushing syste king place. en using do no sh contaminat e effective ope ineering contr ropriate dego	emical is likely during typical use, provide ems and safety showers close to the ot eat, drink or smoke. ed clothing before re-use. ration of a facility should include review of ols, proper personal protective equipment, whing and decontamination procedures, monitoring, medical surveillance and the		

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	colorless
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	6.5 - 8
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available




according to the Hazardous Products Regulations

Interferon Alfa-2b Liquid Formulation

Vers 5.8	sion	Revision Date: 09/30/2023	-	S Number: 03-00018	Date of last issue: 04/04/2023 Date of first issue: 01/07/2015
	Flamma	ability (solid, gas)	:	Not applicable	
	Flammability (liquids)		:	No data available	
	Upper explosion limit / Upper flammability limit		:	No data available	
	Lower explosion limit / Lower flammability limit		:	No data available	
	Vapor p	pressure	:	No data available	
	Relative	e vapor density	:	No data available	
	Relative density		:	No data available	
	Density		:	No data available	
	Solubili Wate	ty(ies) er solubility	:	No data available	
	Partition octanol	n coefficient: n-	:	Not applicable	
		ition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	Viscosit Visc	ty osity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance or	mixture is not classified as oxidizing.
	Molecular weight		:	Not applicable	
	Particle size		:	Not applicable	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability	:	Not classified as a reactivity hazard. Stable under normal conditions.
	:	Can react with strong oxidizing agents.
tions		
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.





Interferon Alfa-2b Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
5.8	09/30/2023	42803-00018	Date of first issue: 01/07/2015

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely route Inhalation Skin contact Ingestion Eye contact	es of	exposure
Acute toxicity		
Not classified based on avai	lable	Information.
<u>Product:</u> Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Components:		
m-Cresol:		
Acute oral toxicity	:	LD50 (Rat): 121 mg/kg Remarks: Based on data from similar materials
Acute inhalation toxicity	:	Assessment: Corrosive to the respiratory tract.
Acute dermal toxicity	:	LD50 (Rabbit): 301 mg/kg Remarks: Based on data from similar materials
Skin corrosion/irritation		
Not classified based on avai	lable	information.
Components:		
m-Cresol:		
Species Result	:	Rabbit Corrosive after 3 minutes to 1 hour of exposure
Interferon alfa-2b:		
Species Result	:	Rat Skin irritation
Serious eye damage/eye ir Not classified based on avai		
Components:		
m-Cresol: Species Result	:	Rabbit Irreversible effects on the eye

according to the Hazardous Products Regulations



Interferon Alfa-2b Liquid Formulation

ersion .8	Revision Date: 09/30/2023		8 Number: 03-00018	Date of last issue: 04/04/2023 Date of first issue: 01/07/2015		
Interf	eron alfa-2b:					
Speci Rema			Rabbit slight irritation			
Rosn	Respiratory or skin sensitization					
-	sensitization	1112011011				
-	assified based on av	ailable ir	formation.			
-	iratory sensitization		formation.			
Germ	cell mutagenicity					
	assified based on av	ailable ir	formation.			
<u>Comp</u>	<u>oonents:</u>					
m-Cr o Geno	esol: toxicity in vitro	I		romosome aberration test in vitro D Test Guideline 473 e		
		1		cterial reverse mutation assay (AMES) D Test Guideline 471 ve		
Geno	toxicity in vivo		cytogenetic te Species: Mous Application Ro	oute: Ingestion D Test Guideline 475		
Interf	eron alfa-2b:					
	toxicity in vitro		Test Type: Ch Result: negativ	romosome aberration test in vitro		
			Test Type: Ba Result: negativ	cterial reverse mutation assay (AMES) ve		
Geno	toxicity in vivo	:	Species: Mous Result: negativ			
Carci	nogenicity					
Not cl	assified based on av	ailable ir	formation.			
Com	oonents:					
m-Cr		-				
Speci Applic	es cation Route		Nouse, males ngestion			
			8 / 13	3		



ersion B	Revision Date: 09/30/2023	-	0S Number: 803-00018	Date of last issue: 04/04/2023 Date of first issue: 01/07/2015
Expos Resul Rema		:	105 weeks equivocal Based on data fro	om similar materials
	cation Route sure time t		Mouse, female Ingestion 106 - 107 weeks positive Based on data fro	om similar materials
Carcii ment	Carcinogenicity - Assess- ment		Weight of evidend cinogen	ce does not support classification as a car-
-	oductive toxicity Jamage fertility. May dar	mag	e the unborn child.	
<u>Comp</u>	oonents:			
m-Cro Effect	esol: s on fertility	:	Test Type: Two-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study
Effect	s on fetal development	:	Test Type: Prena Species: Rat Application Route Result: negative	tal development toxicity study (teratogenicity) :: Ingestion
Interf	eron alfa-2b:			
	s on fertility	:	Test Type: Fertilit Species: Monkey Fertility: LOAEL: 3 Result: menstrual Remarks: Abortio	3.8 μg/kg irregularities
Effect	s on fetal development	:	Species: Monkey	y/early embryonic development oxicity: LOAEL: 3.8 μg/kg body weight thal effects.
Repro sessn	oductive toxicity - As- nent	:	May damage ferti	lity. May damage the unborn child.
	-single exposure assified based on availa	able	information	
STOT-repeated exposure May cause damage to organs (Blood, Bone marrow) through prolonged or repeated exposure) through prolonged or repeated exposure
-	oonents:	ים, י		
	eron alfa-2b:			
	et Organs	:	Blood, Bone marr	OW

according to the Hazardous Products Regulations



Interferon Alfa-2b Liquid Formulation

Assessment : May cause damage to organs through prolonged or replexposure. Repeated dose toxicity Components: m-Cresol: Species : Rat NOAEL :: 150 mg/kg Application Route :: 1 ngestion Exposure time :: 1 3 Weeks Method :: OECD Test Guideline 408 Interferon alfa-2b: Species :: Monkey NOAEL :: 0.095 mg/kg Application Route :: Intramuscular Exposure time :: 1 Months Remarks :: No significant adverse effects were reported Species :: Rat NOAEL :: 0.38 mg/kg Application Route :: Subcutaneous Exposure time :: 3 Months Remarks :: No significant adverse effects were reported Species : Mouse MOAEL : 0.076 mg/kg Application Route :: Intraperitoneal Exposure time :: 0.076 mg/kg Application Route :: Intraperitoneal Exposure time :: 0.38 mg/kg Application Route : No significant adverse eff	
Species : Rat NOAEL : 150 mg/kg Application Route : Ingestion Exposure time : 13 Weeks Method : OECD Test Guideline 408 Interferon alfa-2b: Species : Monkey NOAEL : 0.095 mg/kg Application Route : Intramuscular Exposure time : 1 Months Remarks : No significant adverse effects were reported Species : Rat NOAEL : 0.38 mg/kg Application Route : No significant adverse effects were reported Species : Rat NOAEL : 0.076 mg/kg Application Route : No significant adverse effects were reported Species : Mouse NOAEL : 0.076 mg/kg Application Route : Intraperitoneal Exposure time : 9 d Remarks : No significant adverse effects were reported	peate
m-Cresol: Species : Rat NOAEL : 150 mg/kg Application Route : Ingestion Exposure time : 13 Weeks Method : OECD Test Guideline 408 Interferon alfa-2b: Species : Species : Monkey NOAEL : 0.095 mg/kg Application Route : Intramuscular Exposure time : 1 Months Remarks : No significant adverse effects were reported Species : Rat NOAEL : 0.38 mg/kg Application Route : Subcutaneous Exposure time : 3 Months Remarks : No significant adverse effects were reported Species : Mouse NOAEL : 0.076 mg/kg Application Route : Intraperitoneal Exposure time : 9 d Remarks : No significant adverse effects were reported Species :	
Species:RatNOAEL:150 mg/kgApplication Route:IngestionExposure time:13 WeeksMethod:OECD Test Guideline 408Interferon alfa-2b:Species:MonkeyNOAEL:0.095 mg/kgApplication Route:IntramuscularExposure time:1 MonthsRemarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:SeciesTarget Organs:Blood, Bone marrowRemarks:Significant toxicity observed in testing	
NOAEL: 150 mg/kgApplication Route: IngestionExposure time: 13 WeeksMethod: OECD Test Guideline 408Interferon alfa-2b:Species: MonkeyNOAEL: 0.095 mg/kgApplication Route: IntramuscularExposure time: 1 MonthsRemarks: No significant adverse effects were reportedSpecies: RatNOAEL: 0.38 mg/kgApplication Route: SubcutaneousExposure time: 3 MonthsRemarks: No significant adverse effects were reportedSpecies: RatNOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 3 MonthsRemarks: No significant adverse effects were reportedSpecies: MouseNOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testingAspiration toxicity: Significant toxicity observed in testing	
Application Route:IngestionExposure time:13 WeeksMethod:OECD Test Guideline 408Interferon alfa-2b:Species:MonkeyNOAEL:0.095 mg/kgApplication Route:IntramuscularExposure time:1 MonthsRemarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:Blood, Bone marrowRemarks::Significant toxicity observed in testingAspiration toxicity::Aspiration toxicity:	
Exposure time: 13 Weeks OECD Test Guideline 408Interferon alfa-2b:Species: Monkey 0.095 mg/kg Application RouteIntramuscularExposure time: 1 Months RemarksRemarks: No significant adverse effects were reportedSpecies: Rat NOAELNOAEL: 0.38 mg/kg Application RouteApplication Route: Subcutaneous Exposure timeExposure time: 3 Months RemarksRemarks: No significant adverse effects were reportedSpecies: Rat Subcutaneous Exposure timeSpecies: No significant adverse effects were reportedSpecies: Mouse NOAELNOAEL: 0.076 mg/kg Application RouteSpecies: Mouse NOAELNOAEL: 0.076 mg/kg Application RouteSpecies: Monkey LOAELLOAEL: 0.38 mg/kg Application RouteSpecies: Monkey LOAELLOAEL: 0.38 mg/kg Application RouteSpecies: Monkey LOAELLOAEL: 0.38 mg/kg Application RouteSpecies: Monkey LOAELLOAEL: 0.38 mg/kg Application RouteSpecies: Monkey LOAELKapsure time: 3 Months RemarksManuel Load, Bone marrow RemarksRemarks: Significant toxicity observed in testingAspiration toxicity	
Method : OECD Test Guideline 408 Interferon alfa-2b: Species Species : Monkey NOAEL : 0.095 mg/kg Application Route : Intramuscular Exposure time : 1 Months Remarks : No significant adverse effects were reported Species : Rat NOAEL : 0.38 mg/kg Application Route : Subcutaneous Exposure time : 3 Months Remarks : No significant adverse effects were reported Species : Mouse NOAEL : 0.076 mg/kg Application Route : Intraperitoneal Exposure time : 9 d Remarks : No significant adverse effects were reported Species : Mouse NOAEL : 0.076 mg/kg Application Route : Intraperitoneal Exposure time : 9 d Remarks : No significant adverse effects were reported Species : Monkey LOAEL : 0.38 mg/kg Application Route : Intramuscular Exposure time : 3 Months	
Interferon alfa-2b:Species:: MonkeyNOAEL:: 0.095 mg/kgApplication Route:: IntramuscularExposure time:: 1 MonthsRemarks:: No significant adverse effects were reportedSpecies:: RatNOAEL:: 0.38 mg/kgApplication Route:: SubcutaneousExposure time:: 3 MonthsRemarks:: No significant adverse effects were reportedSpecies:: MouseNOAEL:: 0.076 mg/kgApplication Route:: 0.076 mg/kgApplication Route:: IntraperitonealExposure time:: 9 dRemarks:: No significant adverse effects were reportedSpecies:: MouseNOAEL:: 0.076 mg/kgApplication Route:: IntraperitonealExposure time:: 9 dRemarks:: No significant adverse effects were reportedSpecies:: MonkeyLOAEL:: 0.38 mg/kgApplication Route:: IntramuscularExposure time:: 3 MonthsTarget Organs:: Blood, Bone marrowRemarks:: Significant toxicity observed in testingAspiration toxicity:: Significant toxicity observed in testing	
Species: MonkeyNOAEL: 0.095 mg/kgApplication Route: IntramuscularExposure time: 1 MonthsRemarks: No significant adverse effects were reportedSpecies: RatNOAEL: 0.38 mg/kgApplication Route: SubcutaneousExposure time: 3 MonthsRemarks: No significant adverse effects were reportedSpecies: MouseNOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testingAspiration toxicity: Significant toxicity observed in testing	
NOAEL:0.095 mg/kgApplication Route:IntramuscularExposure time:1 MonthsRemarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:Blood, Bone marrowRemarks:Significant toxicity observed in testingAspiration toxicity:Significant toxicity observed in testing	
NOAEL:0.095 mg/kgApplication Route:IntramuscularExposure time:1 MonthsRemarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:Blood, Bone marrowRemarks:Significant toxicity observed in testingAspiration toxicity:Significant toxicity observed in testing	
Application Route:IntramuscularExposure time:1 MonthsRemarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:Blood, Bone marrowRemarks:Significant toxicity observed in testing	
Exposure time: 1 MonthsRemarks: No significant adverse effects were reportedSpecies: RatNOAEL: 0.38 mg/kgApplication Route: SubcutaneousExposure time: 3 MonthsRemarks: No significant adverse effects were reportedSpecies: MouseNOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testingAspiration toxicity: Significant toxicity observed in testing	
Remarks:No significant adverse effects were reportedSpecies:RatNOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntraperitonealExposure time::::0.38 mg/kgApplication Route:IntramuscularExposure time:::::Species:MonthsTarget Organs::	
NOAEL:0.38 mg/kgApplication Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:Blood, Bone marrowRemarks:Significant toxicity observed in testing	
Application Route:SubcutaneousExposure time:3 MonthsRemarks:No significant adverse effects were reportedSpecies:MouseNOAEL:0.076 mg/kgApplication Route:IntraperitonealExposure time:9 dRemarks:No significant adverse effects were reportedSpecies:MonkeyLOAEL:0.38 mg/kgApplication Route:IntramuscularExposure time:3 MonthsTarget Organs:Blood, Bone marrowRemarks:Significant toxicity observed in testing	
Exposure time: 3 MonthsRemarks: No significant adverse effects were reportedSpecies: MouseNOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Remarks: No significant adverse effects were reportedSpecies: MouseNOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Species : Mouse NOAEL : 0.076 mg/kg Application Route : Intraperitoneal Exposure time : 9 d Remarks : No significant adverse effects were reported Species : Monkey LOAEL : 0.38 mg/kg Application Route : Intramuscular Exposure time : 3 Months Target Organs : Blood, Bone marrow Remarks : Significant toxicity observed in testing	
NOAEL: 0.076 mg/kgApplication Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Application Route: IntraperitonealExposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Exposure time: 9 dRemarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Remarks: No significant adverse effects were reportedSpecies: MonkeyLOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Species : Monkey LOAEL : 0.38 mg/kg Application Route : Intramuscular Exposure time : 3 Months Target Organs : Blood, Bone marrow Remarks : Significant toxicity observed in testing	
LOAEL: 0.38 mg/kgApplication Route: IntramuscularExposure time: 3 MonthsTarget Organs: Blood, Bone marrowRemarks: Significant toxicity observed in testing	
Application Route : Intramuscular Exposure time : 3 Months Target Organs : Blood, Bone marrow Remarks : Significant toxicity observed in testing	
Exposure time : 3 Months Target Organs : Blood, Bone marrow Remarks : Significant toxicity observed in testing Aspiration toxicity	
Target Organs : Blood, Bone marrow Remarks : Significant toxicity observed in testing Aspiration toxicity	
Remarks : Significant toxicity observed in testing Aspiration toxicity	
Aspiration toxicity	
• •	
Not classified based on available information.	
Experience with human exposure	

Interferon alfa-2b:

Skin contact

: Symptoms: The most common side effects are:, flu-like symptoms, Fever, chills, Fatigue

according to the Hazardous Products Regulations



Interferon Alfa-2b Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
5.8	09/30/2023	42803-00018	Date of first issue: 01/07/2015

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 8.6 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l Exposure time: 48 h
Toxicity to fish (Chronic tox- icity)	:	NOEC (Pimephales promelas (fathead minnow)): 1.35 mg/l Exposure time: 32 d Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC (Daphnia magna (Water flea)): 1 mg/l Exposure time: 21 d Remarks: Based on data from similar materials

Persistence and degradability

Components:

m-Cresol:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 90 %
		Exposure time: 28 d Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

m-Cresol:		
Bioaccumulation	:	Species: Leuciscus idus (Golden orfe) Bioconcentration factor (BCF): 17 - 20
Partition coefficient: n-	:	log Pow: 1.96

: log Pow: 1.96

octanol/water Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues

: Do not dispose of waste into sewer.



according to the Hazardous Products Regulations

Interferon Alfa-2b Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
5.8	09/30/2023	42803-00018	Date of first issue: 01/07/2015
Conta	minated packaging	: Empty contain handling site for	accordance with local regulations. ers should be taken to an approved waste or recycling or disposal. e specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.

Domestic regulation

TDG Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations			
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)	
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)	
CA BC OEL	:	Canada. British Columbia OEL	
CA QC OEL	:	Québec. Regulation respecting occupational health and safe- ty, Schedule 1, Part 1: Permissible exposure values for air- borne contaminants	
ACGIH / TWA	:	8-hour, time-weighted average	
CA AB OEL / TWA	:	8-hour Occupational exposure limit	
CA BC OEL / TWA		8-hour time weighted average	
CA QC OEL / TWAEV	:	Time-weighted average exposure value	



Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
5.8	09/30/2023	42803-00018	Date of first issue: 01/07/2015

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Revision Date Date format	:	09/30/2023 mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8